DnB Asset Management AS reduced its position in Eli Lilly and Co (NYSE:LLY) by 22.7% during the 4th quarter, HoldingsChannel reports. The fund owned 233,398 shares of the company’s stock after selling 68,452 shares during the quarter. DnB Asset Management AS’s holdings in Eli Lilly and were worth $19,713,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in LLY. Bank of Nova Scotia grew its position in Eli Lilly and by 918.6% during the first quarter. Bank of Nova Scotia now owns 224,831 shares of the company’s stock valued at $18,910,000 after purchasing an additional 202,758 shares in the last quarter. North Star Asset Management Inc. purchased a new position in Eli Lilly and during the first quarter valued at approximately $224,000. Triangle Securities Wealth Management grew its position in Eli Lilly and by 1.9% during the second quarter. Triangle Securities Wealth Management now owns 13,749 shares of the company’s stock valued at $1,132,000 after purchasing an additional 250 shares in the last quarter. Independent Portfolio Consultants Inc. grew its position in Eli Lilly and by 124.6% during the second quarter. Independent Portfolio Consultants Inc. now owns 2,516 shares of the company’s stock valued at $207,000 after purchasing an additional 1,396 shares in the last quarter. Finally, First American Trust FSB purchased a new position in Eli Lilly and during the second quarter valued at approximately $1,105,000. 76.31% of the stock is currently owned by institutional investors and hedge funds.
In other news, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the sale, the insider now directly owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders sold 251,088 shares of company stock valued at $22,041,236 over the last 90 days. 0.20% of the stock is owned by corporate insiders.
Shares of Eli Lilly and Co (LLY) opened at $86.06 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Co has a one year low of $74.00 and a one year high of $89.09. The stock has a market cap of $94,760.00, a P/E ratio of 40.98, a price-to-earnings-growth ratio of 1.62 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same period in the previous year, the company earned $0.88 earnings per share. Eli Lilly and’s revenue for the quarter was up 9.0% on a year-over-year basis. equities research analysts predict that Eli Lilly and Co will post 4.22 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.61%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s payout ratio is presently 99.05%.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
What are top analysts saying about Eli Lilly and? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and and related companies.